Luteoloside Inhibits Proliferation of Human Chronic Myeloid Leukemia K562 Cells by Inducing G2/M Phase Cell Cycle Arrest and Apoptosis
Purpose: To investigate the effects of luteoloside on the proliferation of human chronic myeloid leukemia K562 cells and whether luteoloside induces cell cycle arrest and apoptosis in K562 cells.
Methods: Luteoloside’s cytotoxicity was assessed using a cell counting kit. Cell cycle distribution was analysed by flow cytometry after propidium iodide (PI) staining. Cell apoptosis was assayed with apoptosis detection kit and Hoechst staining followed by observation under a fluorescence microscope. The expression of cell cycle- and apoptosis-related proteins was examined by Western blot analysis.
Results: Luteoloside inhibited the proliferation of K562 cells in a dose- and time- dependent manner (IC50 = 30.7 μM) with less toxicity in a normal human cell line (IC50 = 91.8 μM). Moreover, antiproliferative effect of luteoloside was accompanied with G2/M phase arrest（p ＜ 0.05 or p＜0.01） and apoptosis（p ＜ 0.01 or p ＜ 0.001）. Further studies revealed that the expression level of cyclinB1 was down-regulated by luteoloside treatment. Furthermore, luteoloside treatment also increased proapoptotic protein Bax expression and decreased anti-apoptotic protein Bcl-2 expression.
Conclusion: These results suggest that the inhibitory effect of luteoloside on K562 cell proliferation is associated with inducing G2/M phase arrest and apoptosis, and that luteoloside is worth further studying for anticancer potential.
Keywords: Luteoloside, Myeloid leukemia, Proliferation, Cell cycle arrest, Apoptosis, Anticancer
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.